The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned HC seeks Novo Nordisk's reply on Natco plea to revoke patent. The response from the Company is attached.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Smallcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma responded to NSE's query regarding a news article about a High Court matter involving Novo Nordisk. The company clarified that the patent litigation has been ongoing for several months and the outcome is still pending. Natco stated there is no undisclosed information that could explain any unusual trading activity, and as of now, the article has no material financial impact on the company. The company confirmed it will update the exchanges once the litigation outcome has a material effect on financial performance. Natco also stated it has been consistently complying with SEBI's listing regulations and disclosure requirements.
No immediate material impact on the company's financials or operations. The stock may see volatility tied to future court developments in the ongoing patent dispute with Novo Nordisk, which remains unresolved.